Exhibit 2 Transplants Performed by Organ and Donor Type, U.S.

1990-95

Year
Organ 1990 1991 1992 1993 1994 1995
Kidney 9880 10122 10230 11021 11392 11807
Liver 2690 2953 3064 3457 3652 3923
Heart 208 2125 2171 2297 2340 2361
Lung 203 405 535 666 723 871
Totals 14881 15605 16000 17441 18107 18962

SOURCE: Compiled from United Network for Organ Sharing web site, 1996.

Exhibit 3 Market Supply by Organ and Donor Type, U.S. 1990-95

Year
Organ 1990 1991 1992 1993 1994 1995
Kidney 6404 6657 6811 7455 7749 8094
Liver 2886 3189 3368 3800 4154 4357
Heart 2181 2202 2248 2444 2529 2506
Lung 276 399 527 802 945 940
Totals 5684 5880 6085 6514 6777 7223

SOURCE: Compiled from United Network for Organ Sharing web site, 1996.
Exhibit 4 Organ Procurement and Transplantation Network Waiting Lists, U.S. 1990-95

Year
Organ 1990 1991 1992 1993 1994 1995
Kidney 17883 19352 22376 24973 28498 31045
Liver 1237 1676 2323 2997 4059 5691
Heart 1788 2267 2690 2834 2933 3468
Lung 308 670 942 140 1625 1923
Totals 21216 23965 28331 30944 37115 42127

SOURCE: Compiled from United Network for Organ Sharing web site, 1996.

Exhibit 5 Mortality While Awaiting Transplant, U.S. 1990-95

Reported Deaths on the Waiting List Median Alternative

Organ 1990 1991 1992 1993 1994 1995 Waiting Treatment
Time Available
Kidney 932 989 1065 1297 1372 1520 6-12 mo. Dialysis
Liver 318 437 495 562 657 804 3-6 mo. None
Heart 614 779 780 764 724 770 2-3 mo. None
Lung 50 139 219 252 286 342 N/A N/A
Totals 1893 2299 2508 2804 2940 3330

SOURCE: Compiled from United Network for Organ Sharing web site, 1996; and Company estimates, compiled
from IPO Prospectus, 1990.
 Mortality
Awaiting
Transplant
35%
25%
35%
N/A

estimates, compiled
Exhibit 6 Potentital Demand Estimates by Indication and Donor Type, U.S. 1990

Annual % Currently # Currently % Potential

Disease Acceptable for Acceptable for Demand for
Organ Indication Incidence Transplant Transplant Transplant
Kidney Chronic Renal Failure 40,000 25% 10,000 75%
Liver End-Stage Liver Disease: 25,000 10% 2,500 50%
Acute Liver Failure 5,000 none none 30%
Heart End-Stage Heart Disease: 100,000 2% 100 30%
Acute Myocardial Infarction 250,000 none 2,000 10%
Lung End-Stage Pulmonary Disease 40,000 1% 400 25%

Current 15,000 Potential

SOURCE: Company estimates, compiled from IPO prospectus, 1990.
# Potential
Demand for
Transplant
30,000
12,500
1,500
30,000
25,000
10,000

110,000
Exhibit 14 BioTransplant Inc. Selected Consolidated Financial Data

Years Ended December 31, (in thousands)

Consolidated Statements of Operations 1991 1992 1993 1994

Revenues:
License fees $ - $ - $ 1,500 $ 1,500
Research and development - - 1,125 1,500
Interest income 14 114 66 163
Total revenues 14 114 2,691 3,163

Expenses:
Research and development 1,821 4,985 8,218 11,767
General and administrative 776 1,235 1,680 2,518
Interest 54 82 542 146
Total expenses 2,651 6,302 10,440 14,431
Net income (loss) $ (2,637) $ (6,188) $ (7,749) $(11,268)

December 31, (in thousands)

Consolidated Balance Sheet 1991 1992 1993

Cash and cash equivalents $ 1,452 $ 2,298 $ 6,880

Working capital 155 1,386 6,225
Total assets 2,241 3,488 8,500
Long-term obligation under capital leases, net of 31 439 334
current portion
Redeemable convertible preferred stock 3,248 10,918 23,029
Stockholders' equity (deficit) (2,753) (8,942) (16,108)

SOURCE: Company records, compiled from IPO prospectus, 1996.

 Period from Inception
1, (in thousands) (March 20 ,1990) to
1995 12/31/1995

$ 4,000 $ 7,000
5,875 8,500
168 525
10,043 16,025

9,461 36,275
1,939 8,266
731 1,566
12,131 46,907
$ (2,087) $ (30,072)

er 31, (in thousands)

1994 1995

$ 2,343 $ 2,489
148 86
4,801 5,372
1,066 615

23,772 29,241
(27,030) (28,840)
Exhibit 15 BioTransplant Inc. Estimated Profit and Loss Statement as of 1996

Years Ended December 31, (in millions)

License fees and hurdles $ 4.0 $ 2.0 $ 5.5 $ 6.5 $ 8.0 $ -

R&D reimbursement 5.9 5.7 9.5 8.5 6.5 6.5
Sales:
BTI-322/MEDI-500 - - - - 6.2 8.4
AlloMune - - - - 17.9 25.6
Total sales - - - - 24.1 34.1
Prepaid royalties - - - - (3.0) (3.0)
Interest income 0.2 1.2 1.4 2.8 2.6 2.6
Total revenues 10.0 8.9 16.4 17.8 38.2 40.1
Expenses:
Research and development 9.5 14.0 16.0 18.0 22.0 20.0
General and administrative 1.9 2.0 3.0 3.5 9.4 12.2
Interest 0.7 0.3 0.3 0.3 0.3 0.3
Cost of goods - - - - 3.8 4.1
Total expenses 12.1 16.3 19.3 21.8 35.5 36.6
EBIT (2.1) (7.4) (2.9) (4.0) 2.7 3.5
Taxes - - - - - -
Net profit (loss) (2.1) (7.4) (2.9) (4.0) 2.7 3.5
Net income (loss) per share (0.44) (0.95) (0.34) (0.36) 0.23 0.29
Weighted shares outstanding 4,707 7,800 8,500 11,000 11,500 12,000

SOURCE: UBS Securities and BioTransplant, compiled from IPO prospectus, 1996.
Exhibit 16 Alexion Pharmaceuticals Inc. Selected Consolidated Financial Data, 1995

Consolidated Statements of Operations July 31,

Revenues: 1994 1995

Sales $ - $ 0.1
Total revenues - 0.1
Total expenses - 7.2
Net income (loss) - (7.1)

Consolidated Balance Sheet Data: 1994 1995

Cash and cash equivalents $ 5.7 $ 18.6

Working capital 3.6 17.0
Total assets 7.9 20.5
Total liabilities 2.8 2.2
Stockholders' equity (deficit) 5.1 18.3

SOURCE: Standard & Poor's Compustat, PC Plus CD-ROM

Exhibit 17 CytoTherapeutics Inc. Selected Consolidated Financial Data, 1991-1995

Consolidated Statements of Operations Years Ended December 31, (in millions)

Revenues 1991 1992 1993 1994 1995

Sales $ 0.5 $ 0.3 $ 0.2 $ 1.3 $ 11.8
Interest income 0.2 1.1 1.1 1.0 1.7
Total revenues 0.7 1.4 1.3 2.3 13.5

Expenses:
Cost of goods sold 0.6 0.2 13.6 16.7 17.9
Depreciation, depletion, and amortization 0.4 0.8 1.5 1.6 1.4
Interest 0.1 0.2 0.4 0.4 0.7
General and administrative 5.9 10.1 - - -
Total expenses 7.1 11.4 13.8 18.8 22.4
Net income (loss) (6.4) (10.0) (12.5) (16.5) (8.9)

Consolidated Balance Sheet Data:

Cash and cash equivalents $ 14.8 $ 10.9 $ 17.3 $ 19.1 $ 44.2

Working capital 13.5 9.4 15.0 15.8 39.7
Total assets 17.3 35.2 41.0 32.2 56.8
Total liabilities 2.3 6.0 6.5 9.6 11.4
Stockholders' equity (deficit) 14.9 29.2 34.5 22.6 45.4

SOURCE: Standard & Poor's Compustat, PC Plus CD-ROM

Exhibit 18 Diacrin Inc. Selected Consolidated Financial Data, 1994-1995

(in millions) Years ended

December 31,

Consolidated Statements of Operation Data 1994 1995

Revenues:

Sales $ 0.4 $ 0.3

Interest income - -
Total revenues 0.4 0.3

Expenses:

Cost of goods sold 6.0 5.4

Other 0.2 0.6
Total expenses 6.2 6.0
Net income (loss) (5.8) (5.7)

Consolidated Balance Sheet Data:

Cash and cash equivalents $ 2.8 $ 4.1

Working capital 1.6 2.8
Total assets 3.7 5.2
Total liabilities 1.8 9.0
Stockholders' equity (deficit) 1.8 (3.9)

SOURCE: Standard & Poor's Compustat, PC Plus CD-ROM

Exhibit 19 SangStat Medical Corp. Selected Consolidated Financial Data, 1992-1995

(in millions) Years ended December 31,

Revenues: 1992 1993 1994 1995

Sales $ 0.5 $ 3.2 $ 3.7 $ 3.8

Interest income 0.1 0.1 0.4 0.8
Total revenues 0.6 3.3 4.1 4.6

Expenses:

Cost of goods sold 0.9 1.6 2.6 3.8

General and administrative 4.4 5.0 6.6 9.0
Depreciation, depletion and amortization 0.2 0.2 0.3 0.3
Interest 0.1 0.1 0.1 0.1
Total expenses 5.7 6.9 9.6 13.4
Net Income (4.9) (3.7) (5.5) (8.7)

Consolidated Balance Sheet Data:

Cash and cash equivalents $ 0.6 $ 10.6 $ 12.4 $ 9.2

Working capital 0.3 9.9 11.4 8.5
Total assets 1.5 12.5 14.4 11.6
Total liabilities 2.3 3.0 3.1 3.3
Stockholders' equity (deficit) (0.8) 9.5 11.3 8.3

SOURCE: Standard & Poor's Compustat, PC CD-ROM

Exhibit 20 Selected Stock Market Data as of January 1996

Alexion CytoTherapeutics Diacrin Sangstat

Stock symbol ALXN CTH DCRN SANG
Share price, month close n/a 17.000 n/a 16.250
Market value n/a 258.0000 n/a 155.9675
Beta 2,217.000 2.477 n/a 2.217
Earnings per share (0.290) (0.200) (0.130) (0.290)
Earliest share price:
Month close Feb 1996 Mar 1992 Feb 1996 Dec 1993
Value 9.2500 8.0000 10.2500 7.0000
Earliest market value:
Month close Feb 1996 Mar 1992 Feb 1996 Dec 1993
Value 36.8613 62.4400 126.8438 46.9560

SOURCE: Standard & Poor's Compustat, PC Plus CD-ROM